Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
This trial is active, not recruiting.
|Condition||carcinoma, non-small-cell lung|
|Treatments||pemetrexed, bi 6727|
|Start date||March 2009|
|End date||September 2012|
|Trial size||143 participants|
|Trial identifier||NCT00824408, 1230.5|
The trial objective will be to evaluate whether BI 6727 monotherapy or in combination with pemetrexed may be effective in the treatment of advanced or metastatic NSCLC in patients who relapsed after or failed first-line platinum based therapy.
The secondary objectives are to identify the acceptable dose of BI 6727 in combination with pemetrexed and to characterize the pharmacokinetic profiles of BI 6727 alone. Arm A, BI6727 monotherapy arm is closed to further recruitment.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Nassau, Bahamas||1230.5.00118 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Edmonton, Canada||1230.5.00104 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Kelowna, Canada||1230.5.00114 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Surrey, Canada||1230.5.00109 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Vancouver, Canada||1230.5.00107 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Hamilton, Canada||1230.5.00105 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Kitchener, Canada||1230.5.00119 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Oshawa, Canada||1230.5.00116 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Ottawa, Canada||1230.5.00108 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Toronto, Canada||1230.5.00110 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Montreal, Canada||1230.5.00106 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Montreal, Canada||1230.5.00102 Boehringer Ingelheim Investigational Site||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
Progression free survival time (PFS) from the date of randomization to the earlier date of disease progression or death.
time frame: 12 months
Objective tumor response, defined as complete response (CR), and partial response (PR), evaluated according to RECIST; Overall survival; Duration of overall response; Pharmacokinetic characteristics of BI 6727 and pemetrexed;occurence and intensity of AE
time frame: 8 months
Male or female participants at least 18 years old.
Inclusion criteria: 1. Pathologic or cytologic confirmed diagnosis of NSCLC 2. Recurrent, advanced or metastatic NSCLC that has progressed following one prior platinum based chemotherapy regimen (not counting adjuvant or neoadjuvant chemotherapy if completed more than 12 months prior to platinum based therapy) 3. Patients who are eligible for pemetrexed as second line chemotherapy 4. Measurable disease by one or more techniques (CT, MRI) according to RECIST 5. Patients aged 18 years or older 6. Life expectancy of at least three (3) months 7. Eastern Cooperative Oncology Group (ECOG) performance Score 0-2 8. Written informed consent that is consistent with ICH-GCP guidelines and local legislation Exclusion criteria: 1. Treatment with an investigational drug in another clinical study within the past 28 days prior to the start of therapy or concomitantly with this study 2. Anti-cancer therapy for NSCLC (except radiotherapy for palliative reasons) within the past 28 days prior to Treatment Day 1 of Cycle 1 of this trial 3. Any persisting toxicities which are deemed to be clinically significant from the previous therapy 4. Patients who have received more than one prior chemotherapy regimen for advanced disease (not including prior adjuvant therapy). Patients may have received prior epidermal growth factor receptor tyrosine kinase inhibitors. 5. Patients who are unwilling or unable to take folic acid and vitamin B12 supplementation 6. Active brain metastases (stable for <28 days, symptomatic, or requiring concurrent steroids). Patients who have received prior whole brain irradiation and whose brain metastases are stable according to the criteria above will not be excluded. 7. Other active malignancy diagnosed within the past 3 years (other than non melanomatous skin cancer and cervical intraepithelial neoplasia) 8. Concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug 9. Patients unable or unwilling to interrupt concomitant administration of NSAIDS 5 days prior to, the day of and 2 days after the administration of pemetrexed, with the exception of lose dose aspirin 81mg daily 10. Patients who have received prior therapy with pemetrexed 11. Absolute neutrophil count (ANC) less than 1,500/mm3 12. Platelet count less than 100,000/mm3 13. Hemoglobin <90g/L 14. Total bilirubin >26µmol/L 15. Alanine amino transferase (ALT) and/or aspartate amino transferase (AST) less than 2.5 X ULN, except in case of known liver metastasis where maximum 5 X ULN is acceptable 16. Serum creatinine level >133µmol/L and/or creatinine clearance (measured or calculated) <45 ml/min 17. Clinically relevant QTc prolongation 18. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception 19. Pregnancy or breast feeding 20. Known or suspected active alcohol or drug abuse 21. Patients unable to comply with the protocol 22. Any known hypersensitivity to the trial drugs or their excipients
|Official title||A Randomised Open-label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-small Cell Lung Cancer|
Call for more information